CRISPR Therapeutics (NASDAQ:CRSP) Raised to “Sell” at StockNews.com
MarketBeatStockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Tuesday.
StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Tuesday.